Chimeric antigen receptor T (CAR-T) cell therapy is a promising immunotherapy for treating cancer, but it requires careful monitoring of the cellular kinetics and biodistribution of the modified cells in patients. One of the challenges in this field is to accurately quantify the transgene copy number and the percentage of modified cells at the DNA level. Digital PCR (dPCR) is a novel technology that can overcome these limitations by separating each PCR reaction into thousands of individual partitions. The partitions are individually counted as positive or negative to directly quantify the sample without a standard curve. 

This webinar will provide an introduction to, and describe the evolution of, CAR-T therapies. Two case studies that apply digital PCR to the monitoring of CAR-T therapies will be presented.

• Case Study 1: Multiplexed CAR-T assays for next-generation, multi-domain therapies using the QIAcuity Digital PCR System.
• Case Study 2: Monitoring multiple approved CAR-T therapies with a single dPCR assay: benefits and challenges for next generation clinical trials.